3B Blackbio DX
- Market cap
- ₹ 1,139 Cr.
- P/E
- 21.1x
- P/B
- 3.57x
- 52-week range
- 1,085 – 1,740
- ROE
- 20%
- ROCE
- 25%
- Dividend yield
- 0.4%
- Debt / equity
- 0.01
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- NSE, BSE
About
3B Blackbio DX Limited is an India-based company, which is engaged in the field of polymerase chain reaction (PCR)-based Molecular Diagnostic Kits. Its segments include Agrochemicals and Diagnostic kits. The diagnostics division of the Company is engaged in Design, Development Manufacturing and Commercialization of qPCR tests, Rapid tests, Next Gen Sequencing (NGS)-based Molecular Diagnostic Kits and Extraction Kits for reliable testing on patient samples. Its products include Oncology and Hematology, Antimicrobial Resistance, Infectious Diseases, Human Genetics, Extraction, and Rapid Antigen Kits. The PCR-based Molecular Diagnostic Kits are commercialized with TRUPCR brand to renowned diagnostics labs across the country. The Company also has a Lateral Flow Assays Vertical and a NGS Assay development division. The lateral flow assays are commercialized under the brand name TRURAPID and the NGS assays are commercialized under the brand name TRUNGS.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →3B Blackbio DX against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)21.1 against a typical 21: pricier than most peers (1st = cheapest).18th of 34
- Sales growth+50.7% against a typical +19.1% from a year earlier.4th of 31
- Profit growth−29% against a typical +25.2% from a year earlier.17th of 24
- Share price, 3 months+7.8% against a typical −7.7%.6th of 33
- Size₹ 1,138.8 Cr. market value against a typical ₹ 83 Cr. (1st = largest).8th of 34
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19 | 18 | 23 | 19 | 29 | 25 | 23 | 22 | 34 | 50 | 35 | 33 |
| Expenses | 11 | 9 | 13 | 8 | 13 | 10 | 15 | 10 | 19 | 29 | 27 | 25 |
| Operating Profit | 8 | 9 | 10 | 11 | 16 | 15 | 8 | 12 | 15 | 22 | 8 | 9 |
| OPM % | 40.6% | 50.2% | 43% | 56.4% | 55.5% | 59.4% | 35.2% | 53.2% | 43.5% | 43.1% | 24% | 25.4% |
| Other Income | 3 | 3 | 4 | 4 | 3 | 3 | 5 | 4 | 6 | 6 | 10 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 1 |
| Profit before tax | 10 | 11 | 14 | 14 | 19 | 18 | 13 | 16 | 20 | 27 | 15 | 13 |
| Tax % | 26% | 23.7% | 36% | 21.3% | 23% | 24.2% | 35.9% | 20.3% | 23.3% | 16.4% | 33.1% | 32.1% |
| Net Profit | 8 | 9 | 9 | 11 | 15 | 13 | 8 | 13 | 15 | 22 | 10 | 9 |
| EPS in Rs | 10.46 | 10.16 | 10.33 | 12.97 | 17.07 | 15.61 | 9.79 | 14.67 | 17.14 | 25.32 | 11.14 | 11.1 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 23%
- 5 Years
- −9%
- 3 Years
- 32%
- TTM
- 54%
- 10 Years
- 68%
- 5 Years
- −12%
- 3 Years
- 31%
- TTM
- 13%
- 10 Years
- 58%
- 5 Years
- 17%
- 3 Years
- 23%
- TTM
- —
- 10 Years
- 27%
- 5 Years
- 18%
- 3 Years
- 18%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| 3B Blackbio DX | ₹ 1,370.00 | ₹ 1,139 Cr. | 21.1x | 3.6x | 20% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 99.6x | 26.6x | 31.4% | 17.7% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.6x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 110.5x | 14.2x | 13.6% | 21.7% |
Management
- Dhirendra K. Dubey
- Chairman of the Board, Managing Director
- Navneet Kaur
- Compliance Officer, Company Secretary
- Nikhil K. Dubey
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.